Dataset Information

Open-source data management system for Parkinson's disease follow-up.

ABSTRACT:

Background

Parkinson's disease (PD) is a neurodegenerative condition of the central nervous system that causes motor and non-motor dysfunctions. The disease affects 1% of the world population over 60 years and remains cureless. Knowledge and monitoring of PD are essential to provide better living conditions for patients. Thus, diagnostic exams and monitoring of the disease can generate a large amount of data from a given patient. This study proposes the development and usability evaluation of an integrated system, which can be used in clinical and research settings to manage biomedical data collected from PD patients.

Methods

A system, so-called Sistema Integrado de Dados Biomédicos (SIDABI) (Integrated Biomedical Data System), was designed following the model-view-controller (MVC) standard. A modularized architecture was created in which all the other modules are connected to a central security module. Thirty-six examiners evaluated the system usability through the System Usability Scale (SUS). The agreement between examiners was measured by Kendall's coefficient with a significance level of 1%.

Results

The free and open-source web-based system was implemented using modularized and responsive methods to adapt the system features on multiple platforms. The mean SUS score was 82.99 ± 13.97 points. The overall agreement was 70.2%, as measured by Kendall's coefficient (p < 0.001).

Conclusion

According to the SUS scores, the developed system has good usability. The system proposed here can help researchers to organize and share information, avoiding data loss and fragmentation. Furthermore, it can help in the follow-up of PD patients, in the training of professionals involved in the treatment of the disorder, and in studies that aim to find hidden correlations in data.

SUBMITTER: Folador JP

PROVIDER: S-EPMC7959639 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:JSim is a simulation system for developing models, designing experiments, and evaluating hypotheses on physiological and pharmacological systems through the testing of model solutions against data. It is designed for interactive, iterative manipulation of the model code, handling of multiple data sets and parameter sets, and for making comparisons among different models running simultaneously or separately. Interactive use is supported by a large collection of graphical user interfaces for model writing and compilation diagnostics, defining input functions, model runs, selection of algorithms solving ordinary and partial differential equations, run-time multidimensional graphics, parameter optimization (8 methods), sensitivity analysis, and Monte Carlo simulation for defining confidence ranges. JSim uses Mathematical Modeling Language (MML) a declarative syntax specifying algebraic and differential equations. Imperative constructs written in other languages (MATLAB, FORTRAN, C++, etc.) are accessed through procedure calls. MML syntax is simple, basically defining the parameters and variables, then writing the equations in a straightforward, easily read and understood mathematical form. This makes JSim good for teaching modeling as well as for model analysis for research. For high throughput applications, JSim can be run as a batch job. JSim can automatically translate models from the repositories for Systems Biology Markup Language (SBML) and CellML models. Stochastic modeling is supported. MML supports assigning physical units to constants and variables and automates checking dimensional balance as the first step in verification testing. Automatic unit scaling follows, e.g. seconds to minutes, if needed. The JSim Project File sets a standard for reproducible modeling analysis: it includes in one file everything for analyzing a set of experiments: the data, the models, the data fitting, and evaluation of parameter confidence ranges. JSim is open source; it and about 400 human readable open source physiological/biophysical models are available at http://www.physiome.org/jsim/.

Project description:INTRODUCTION:So far there is no uniform, commonly accepted diagnostic and therapeutic algorithm for patients with embolic stroke of undetermined source (ESUS). Recent clinical trials on secondary stroke prevention in ESUS did not support the use of oral anticoagulation. As ESUS comprises heterogeneous subgroups including a wide age-range, concomitant patent foramen ovale (PFO), and variable probability for atrial fibrillation (AF), an individualised approach is urgently needed. This prospective registry study aims to provide initial data towards an individual, structured diagnostic and therapeutic approach in ESUS patients. METHODS AND ANALYSIS:The open-label, investigator-initiated, prospective, single-centre, observational registry study (Catch-up-ESUS) started in 01/2018. Consecutive ESUS patients ?18 years who give informed consent are included and will be followed up for 3?years. Stratified by age <60?or ?60 years, the patients are processed following a standardised diagnostic and treatment algorithm with an interdisciplinary design involving neurologists and cardiologists. Depending on the strata, patients receive a transesophageal echocardiogram; all patients receive an implantable cardiac monitor. Patients <60 years with PFO and without evidence of concomitant AF are planned for PFO closure within 6 months after stroke. The current diagnostic and therapeutic workup of ESUS patients requires improvement by both standardisation and a more individualised approach. Catch-up-ESUS will provide important data with respect to AF detection and PFO closure and will estimate stratified stroke recurrence rates after ESUS. ETHICS AND DISSEMINATION:The study has been approved by the responsible ethics committee at the Ludwig Maximilian University, Munich, Germany (project number 17-685). Catch-Up-ESUS is conducted in accordance with the Declaration of Helsinki. All patients will have to give written informed consent or, if unable to give consent themselves, their legal guardian will have to provide written informed consent for their participation. The first observation period of the registry study is 1?year, followed by the first publication of the results including follow-up of the patients. Further publications will be considered according the predefined individual follow-up dates of the stroke patients up to 36 months. TRIAL REGISTRATION NUMBER:Clinicaltrialsregister.gov registry (NCT03820375).